NCT01362764View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of Two Abiraterone Acetate Suspension Formulations Compared to the Abiraterone Acetate Tablet Formulation in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2011

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions
Healthy Volunteers
Interventions
DRUG

Abiraterone acetate suspension Formulation 1

Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL

DRUG

Abiraterone acetate suspension Formulation 2

Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL

DRUG

Abiraterone acetate tablets

Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose

Sponsors
All Listed Sponsors
lead

Cougar Biotechnology, Inc.

INDUSTRY